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Introduction {#ijc32614-sec-0001}
============

Cytology‐based cervical screening has reduced the incidence of and mortality from cervical cancer.[1](#ijc32614-bib-0001){ref-type="ref"} However, with an estimated 570,000 new cases in 2018, cervical cancer still is the fourth most common cancer in women worldwide, and accounts for 7.5% of all female cancer deaths, with the majority occurring in low‐ and middle‐income settings.[2](#ijc32614-bib-0002){ref-type="ref"} To facilitate a further reduction in cervical cancer incidence, an increasing number of countries are converting from cytology‐based screening to high‐risk human papillomavirus (hrHPV)‐based screening,[3](#ijc32614-bib-0003){ref-type="ref"} which provides better protection against cervical cancer and precancer.[4](#ijc32614-bib-0004){ref-type="ref"} Yet, given the 3--5% lower specificity of hrHPV testing compared to cytology, objective molecular triage tests are needed to identify hrHPV‐positive women with clinically relevant disease.[4](#ijc32614-bib-0004){ref-type="ref"}, [5](#ijc32614-bib-0005){ref-type="ref"}

Since changes in host cell DNA methylation after a transforming hrHPV infection are central in cervical carcinogenesis, DNA methylation analysis has emerged as a promising and objective triage tool for hrHPV‐positive women.[6](#ijc32614-bib-0006){ref-type="ref"} A number of studies have shown that host cell DNA methylation levels in cervical scrapes increase with underlying cervical disease severity and are highest in cervical cancer.[7](#ijc32614-bib-0007){ref-type="ref"}, [8](#ijc32614-bib-0008){ref-type="ref"}, [9](#ijc32614-bib-0009){ref-type="ref"}, [10](#ijc32614-bib-0010){ref-type="ref"}, [11](#ijc32614-bib-0011){ref-type="ref"}, [12](#ijc32614-bib-0012){ref-type="ref"} Accordingly, methylation biomarkers, including family with sequence similarity 19 (chemokine (C--C)‐motif)‐like) member A4 (*FAM19A4*) and microRNA 124‐2 (*miR124‐2*) genes, have been proposed as objective molecular triage tools for hrHPV‐positive women that allow the identification of women with cervical cancer or cervical intraepithelial neoplasia (CIN) lesions with a cancer‐like methylation profile that have a high risk of progression to cancer.[6](#ijc32614-bib-0006){ref-type="ref"}, [13](#ijc32614-bib-0013){ref-type="ref"}, [14](#ijc32614-bib-0014){ref-type="ref"}, [15](#ijc32614-bib-0015){ref-type="ref"}, [16](#ijc32614-bib-0016){ref-type="ref"} Furthermore, recent longitudinal studies showed that hrHPV‐positive women negative for *FAM19A4/miR124‐2* methylation have a similar risk of CIN3+, and lower risk of cervical cancer, at 14 years from the result as compared to hrHPV‐positive, cytology‐negative women.[17](#ijc32614-bib-0017){ref-type="ref"}, [18](#ijc32614-bib-0018){ref-type="ref"} Collectively, these data support the perspective of utilizing *FAM19A4*/*miR124‐2* methylation analysis as an indicator of clinically significant cervical disease.

Demonstration of performance consistency of *FAM19A4/miR124‐2* methylation analysis to detect cervical cancer is clearly important if this approach is to be used routinely as a triage test. So far, studies have largely been performed on populations from the Netherlands and encouraging clinical performance has been demonstrated at the level of CIN3+. However, these studies included relatively small sample series of invasive cervical cancers, comprising mainly squamous cell carcinomas.[8](#ijc32614-bib-0008){ref-type="ref"}, [13](#ijc32614-bib-0013){ref-type="ref"}, [14](#ijc32614-bib-0014){ref-type="ref"} The aim of the present study was to determine test positivity rates of the *FAM19A4*/*miR124‐2* methylation assay in a global series of cervical carcinomas, with a particular interest in histotypes that have not been studied in marked numbers up till now, including adenocarcinomas, adenosquamous carcinomas and rare types of cervical cancer such as hrHPV‐negative, neuroendocrine and clear cell carcinomas.

Methods {#ijc32614-sec-0002}
=======

Clinical specimens {#ijc32614-sec-0003}
------------------

A multicenter, retrospective study was designed within the VALID‐SCREEN framework, a project funded by the EU Horizon 2020 program (project ID 666800), to determine the *FAM19A4*/*miR124‐2* methylation positivity rate in cervical specimens of women with invasive cervical cancer. In total, 541 DNA extracts derived from cervical scrapes and cervical tissue samples (fresh frozen biopsies or formalin‐fixed, paraffin‐embedded biopsies) from screening or gynecologic outpatient populations from over 25 countries across five continents, were retrieved with DNA isolation performed according to local protocols. Data on the hrHPV status, hrHPV genotype, FIGO stage and pathology diagnosis of the cervical cancer specimens were obtained from the parent institutes. All participating institutes used clinically validated hrHPV DNA assays[19](#ijc32614-bib-0019){ref-type="ref"} to determine hrHPV status and hrHPV genotype (if applicable). In samples testing hrHPV‐negative with a clinically validated hrHPV assay, additional HPV testing was performed with SPF~10~‐LiPA~25~ (Version‐1; Labo Biomedical Products, Rijswijk, The Netherlands) given this assay\'s high analytical sensitivity for detection of HPV.[20](#ijc32614-bib-0020){ref-type="ref"} The cervical cancer histotype was classified according the WHO classification.[21](#ijc32614-bib-0021){ref-type="ref"} Clinical cancer staging was done using the FIGO stage version operative at time of cervical cancer diagnosis.[22](#ijc32614-bib-0022){ref-type="ref"} The work in this study with human‐derived material was conducted under national and international rules and legislation, as well as European standards of research ethics, as it is expressed in the applicable legislation/regulations (The Declaration of Helsinki; informed consent for participation of human subjects in medical and scientific research) and guidelines for Good Clinical Practice. The study was approved by the local ethics committees.

qMSP‐based methylation analysis {#ijc32614-sec-0004}
-------------------------------

Aliquots of isolated DNA were shipped to the pathology department of Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands. DNA was subjected to bisulphite treatment using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA) as described previously.[23](#ijc32614-bib-0023){ref-type="ref"} Bisulfite‐converted DNA was used as template for DNA methylation analysis for *FAM19A4* and *miR124‐2* genes using the QIAsure Methylation Test® (QIAGEN, Hilden, Germany) and was performed on the Rotorgene PCR‐platform (QIAGEN). The housekeeping gene β‐actin (*ACTB*) was used as a reference to assure successful bisulfite conversion, sample quality and normalization. A total of 22 (4.1%) samples were excluded from further analysis due to invalid *FAM19A4/miR124‐2* methylation results, resulting in a final case series of 519 cervical carcinomas. The ΔΔCt values for *FAM19A4* and *miR124‐2* were calculated according to the manufacturer\'s instructions.

Data and statistical analysis {#ijc32614-sec-0005}
-----------------------------

Cervical scrapes were scored positive for methylation based on preset ΔΔCt value thresholds according to the manufacturer\'s instructions. Thresholds for *FAM19A4/miR124‐2* methylation analysis on cervical tissue samples were defined in a training set according to a predefined CIN3+ specificity of 70%. The 95% (exact) CI\'s were determined for the proportions of methylation‐positive samples. The proportions of the methylation‐positive samples per subcategory of histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region were compared using the Fishers' exact test. Median age within groups was compared using the Mann--Whitney U test. For hrHPV genotyping, infections were categorized using hierarchical attribution, which categorizes hrHPV genotypes based on the genotype prevalence in our total series of cervical cancer. In our study population, HPV16 followed by HPV18 were the most prevalent genotypes, resulting in the following categories: (1) HPV16‐positive, (2) HPV16‐negative, HPV18‐positive and (3) HPV16/18‐negative, non‐16/18 hrHPVpositive. In cancers with multiple hrHPV infections, the more prevalent genotype was attributed to the case (e.g., an HPV16 and 18‐positive carcinoma was placed in Category 1). The interquartile range (IQR) was defined as the difference between the first and third quartiles. Analyses were performed in R (version 3.2.5, Vienna, Austria), SPSS statistics (version 22, IBM Corp, Armonk, NY) and Excel.

Results {#ijc32614-sec-0007}
=======

Case series {#ijc32614-sec-0008}
-----------

A flowchart of the study is presented in Figure [1](#ijc32614-fig-0001){ref-type="fig"}. The 519 invasive cervical carcinoma cases with a valid methylation result in our study comprised squamous cell carcinomas (*n* = 318), adenocarcinomas (*n* = 123), adenosquamous cell carcinomas (*n* = 42), other rare histotypes (*n* = 32) and histotype not specified (*n* = 4). The group of rare cervical cancer histotypes consisted of clear cell carcinomas (*n* = 14), neuroendocrine carcinomas (*n* = 13), adenocarcinoma mixed with neuroendocrine carcinoma (*n* = 1), mucinous adenocarcinoma gastric type (*n* = 2), mucinous adenocarcinoma, NOS (*n* = 1) and serous adenocarcinoma (*n* = 1). The median age of the women was 46.0 years (IQR; 38--56).

![Study flowchart. Abbreviations: hrHPV, high‐risk human papillomavirus; qMSP, quantitative methylation‐specific PCR.](IJC-147-1215-g001){#ijc32614-fig-0001}

High‐risk HPV {#ijc32614-sec-0009}
-------------

Overall, 489 out of the 519 cancer cases were positive for hrHPV DNA, resulting in a hrHPV positivity rate of 94.2% (489/519; 95% CI: 91.9--96.1). Genotyping results were available for 429 out of the 489 hrHPV‐positive cancers. Based on hierarchical attribution, 255 cervical carcinoma were positive for HPV16 (59.4%), 92 for HPV18 (21.4%), and 82 for non‐16/18 hrHPV genotypes (19.1%). Of the initial 30 hrHPV‐negative cases, 10 tested positive with the additional SPF~10~‐LiPA~25~ assay, including 2 HPV16, 2 HPV18 and 6 non‐16/18 hrHPV types. One case was excluded from retesting with the SPF~10~‐LiPA~25~ assay due to insufficient residual sample, leaving 19 (3.7%) samples that remained negative for hrHPV DNA.

*FAM19A4/miR124‐2* methylation analysis {#ijc32614-sec-0010}
---------------------------------------

In total, 510 out of the 519 cancer cases tested positive for *FAM19A4/miR124‐2* methylation, which yielded a methylation positivity rate of 98.3% (95% CI: 96.7--99.2). Table [1](#ijc32614-tbl-0001){ref-type="table"} shows the methylation positivity rates stratified for histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region. When considering results from clinically validated hrHPV assays only, a lower proportion of hrHPV‐negative samples tested methylation‐positive as compared to hrHPV‐positive samples: 90.0% (27/30, 95% CI: 73.5--97.9) *vs*. 98.8% (483/489; 95% CI: 97.3--99.5), *p* = 0.012. However, this observation did not hold when the analysis was restricted to consistently hrHPV‐negative cases based on additional SPF~10~‐LiPA~25~ testing with a methylation assay positivity rate of 94.7% (18/19; 95% CI: 74.0--99.9), *p* = 0.235. There was no difference in methylation positivity rates between hrHPV genotype, histotype, FIGO stage, sample type tested or geographical region (Table [1](#ijc32614-tbl-0001){ref-type="table"}). In addition, no difference in median age between women with methylation‐positive (46 years, IQR 38--56) and methylation‐negative carcinomas (55 years, IQR 31--57) was found (*p* = 0.841).

###### 

*FAM19A4/miR124‐2* positivity rates stratified per histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region

  ------------------------------------
  ![](IJC-147-1215-g002.jpg "image")
  ------------------------------------

Considering the relative contribution of each marker, overall 410 cases (79.0%; 95% CI: 75.2--82.4) tested positive for both *FAM19A4* and *miR124‐2* genes, 72 (13.9%; 95% CI: 11.0--17.1) tested single *FAM19A4* methylation‐positive and 28 (5.4%; 95% CI: 3.6--7.7) tested single *miR124‐2* methylation‐positive. This frequency distribution was similar in subgroups based on hrHPV genotype, FIGO stage, sample type tested and geographical region. A higher proportion of samples was observed to be single *miR124‐2* methylation‐positive in the consistently hrHPV‐negative cases as compared to the hrHPV‐positive cases (63.2% *vs*. 2.9%, *p* \< 0.0001) and in rare histotypes as compared to the other histotypes merged as a group (28.1% *vs*. 3.9%, *p* \< 0.0001).

Discussion {#ijc32614-sec-0011}
==========

In our study, we evaluated *FAM19A4/miR124‐2* methylation analysis in a large, worldwide series of cervical cancer, and demonstrated a positivity rate of over 98%. To the best of our knowledge, our study is the largest assessment of host cell DNA methylation in invasive cervical cancer to date. We showed that *FAM19A4/miR124‐2* methylation is common to cervical cancer worldwide, including rare histotypes and hrHPV‐negative carcinomas. These results indicate that the *FAM19A4/miR124‐2* methylation assay has a high sensitivity for cervical cancer and that a negative test result is likely to rule out the presence of cervical cancer.

Our data add a series of over 500 cases and show that aberrant *FAM19A4/miR124‐2* methylation is rather universal to cervical carcinogenesis given that nearly all invasive cervical cancers were methylation‐positive for these human genes. This finding is in line with earlier studies using research tests on the same or different host cell genes but with lower numbers of included samples. In a Dutch series of 79 cervical carcinomas, *CADM1/MAL/miR124‐2* methylation analysis identified 100% of the cervical cancers and in a series of 22 women, *FAM19A4* detected all cervical carcinomas.[8](#ijc32614-bib-0008){ref-type="ref"}, [13](#ijc32614-bib-0013){ref-type="ref"} In addition to this, *FAM19A4* detected 93.4% (57/61) of the cervical cancer cases in a Chinese cohort.[15](#ijc32614-bib-0015){ref-type="ref"} Furthermore, a four‐gene methylation marker panel consisting out of the genes *JAM3*, *EPB41L3*, *TERT* and *C13ORF18* detected 94.2% (65/69) of cervical carcinomas.[10](#ijc32614-bib-0010){ref-type="ref"}

The major strengths of our study are its large size, the inclusion of cases from over 25 countries and the use of a standardized *FAM19A4/miR124‐2* methylation assay, with high intralaboratory and interlaboratory agreement as demonstrated in a recent international study.[24](#ijc32614-bib-0024){ref-type="ref"} The present study indicates that the predefined methylation marker cut‐offs for test positivity appear independent of the population.

The current series of cervical cancers represented the most common histotypes, that is, squamous cell carcinomas and adeno(squamous)carcinomas, various rare histotypes including clear cell carcinomas and neuroendocrine carcinomas, and hrHPV‐negative cervical carcinomas. It should however be noted that this case series was selected for cases with sufficient DNA for methylation analysis and enriched for adeno(squamous)carcinomas, rare histotypes and hrHPV‐negative cervical carcinomas. Accordingly, this case series does not accurately represent the cervical cancer histotype distribution in the general population.

Although persistent hrHPV infection has been identified as the key causative agent for the development of cervical cancer,[25](#ijc32614-bib-0025){ref-type="ref"} a (small) proportion of cervical carcinomas test hrHPV‐negative, as also confirmed in our series with very sensitive SPF~10~‐LiPA~25~ testing. It has been shown that these cases can be reclassified by surgical screening as either malignant tumors of other origin or finally as true hrHPV‐negative cervical cancers.[26](#ijc32614-bib-0026){ref-type="ref"} Though rare, these cancer cases represent a challenge using hrHPV‐based screening methods. Since we showed that the *FAM19A4/miR124‐2* methylation positivity rate was also high in this subgroup of hrHPV‐negative carcinomas, combining the *FAM19A4/miR124‐2* methylation assay with HPV screening could exclude prevalent cancer with high reassurance. In addition, DNA methylation analysis on cervical scrapes might have the potential to detect noncervix gynecological cancers, like endometrial and ovarian carcinomas.[8](#ijc32614-bib-0008){ref-type="ref"}, [27](#ijc32614-bib-0027){ref-type="ref"} Our data indicate that also most cervical cancer cases with a rare histotype test *FAM19A4/miR124‐2* methylation‐positive. The complementarity between *FAM19A4/miR124‐2* methylation analysis was particularly noticeable in this subgroup, as well as in hrHPV‐negative carcinomas, allowing the combination of the two markers to consistently detect cervical cancer.

A limitation of our study, however, is that the number of rare cervical cancer histotypes remains relatively low despite the inclusion of samples from five continents, and hence needs to be expanded in further research for other histotypes than clear cell carcinomas and neuroendocrine carcinomas. In addition, the statistical analysis between subgroups should be interpreted with care, since comparisons were made with very small groups of *FAM19A4/miR124‐2* methylation negative cancers. Another limitation of our study is that we were unable to evaluate additional H&E slides to assess whether a negative hrHPV test and/or a negative methylation test was caused by a very low or absent tumor fraction in the tested sample. Furthermore, given the retrospective design, not all data such as hrHPV genotype, cytology of the cervical scrapes or FIGO stage were available for all samples. It was noted, however, that all scrapes with known normal cytology (7 out of 7) and 99.0% of known FIGO stage I samples (191 out of 193) tested *FAM19A4/miR124‐2* methylation‐positive. These findings are consistent with previous data of DNA hypermethylation being an early event in cervical cancer,[15](#ijc32614-bib-0015){ref-type="ref"}, [28](#ijc32614-bib-0028){ref-type="ref"} and support the potential of the methylation test for use in population‐based screening where most cervical cancers are early‐stage cancers.

The findings of our study highlight the value of *FAM19A4/miR124‐2* methylation analysis as test with a very high sensitivity for cervical cancer, which is an essential characteristic of a triage test. An earlier study has shown that this translates into a low 14‐year cancer risk among hrHPV‐positive, methylation‐negative women (1.7%),[17](#ijc32614-bib-0017){ref-type="ref"} and recently Dick *et al*. reported that a negative *FAM19A4/miR124‐2* methylation triage test provides a similar long‐term CIN3+ risk compared to a negative cytology triage test among hrHPV‐positive women of 30 years and older.[18](#ijc32614-bib-0018){ref-type="ref"} Altogether, these data indicate that further prospective studies are warranted to confirm the value of the *FAM19A4/miR124‐2* methylation test as a safe triage alternative in hrHPV‐based screening programs. As *FAM19A4/miR124‐2* methylation analysis is applicable to either a physician‐taken cervical scrape or a self‐collected specimen,[29](#ijc32614-bib-0029){ref-type="ref"} objective, full molecular screening can be envisioned.

Overall, an approach combining hrHPV screening with methylation biomarkers, with or without supporting cytology, could allow for a more personalized screening with an improved balance between detection of treatment requiring disease and overtreatment, compared to the current implemented or proposed primary hrHPV‐based screening models. The combination of the *FAM19A4/miR124‐2* methylation assay with hrHPV testing could provide marked reassurance for the subset of cases that are missed by hrHPV testing, especially when the high sensitivity of methylation analysis for adenocarcinoma and hrHPV‐negative cancers will also apply to adenocarcinoma *in situ* (AIS) and other non‐HPV‐related (glandular) high‐grade precursors.[8](#ijc32614-bib-0008){ref-type="ref"}, [30](#ijc32614-bib-0030){ref-type="ref"} Furthermore, with increasing uptake of prophylactic HPV vaccines, *FAM19A4/miR124‐2* methylation analysis might be a good assay to rule out cervical cancers whether caused by hrHPV infection prior to vaccination, hrHPV genotypes not covered by the current prophylactic vaccines or characterized by the absence of hrHPV.

In conclusion, our study shows that methylation analysis of *FAM19A4* and *miR124‐2* genes detects nearly all cervical carcinomas, independent of histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region. These results indicate that a negative *FAM19A4/miR124‐2* methylation assay result is likely to rule out the presence of cervical cancer.

Disclaimer {#ijc32614-sec-1013}
==========
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